The Seprion ligand range of products detects aggregated proteins. We have products for monitoring the aggregation state of manufactured therapeutic proteins such as antibodies and for detection of aggregated proteins associated with disease including Parkinson’s, Alzheimer’s, Huntington’s and the Transmissible Spongiform Encephalopathies such as BSE, scrapie, vCJD and CWD.

For diagnosis, detection and research studies it is very difficult to differentiate the abnormal aggregated form of the proteins from the normal unaggregated form.  To address this problem, Microsens has developed polymeric ligands (the ‘Seprion’ range) which only bind to the abnormal or altered aggregated form of the protein.  The Seprion ligands have been shown to bind aggregated antibodies, abnormal prion, β-amyloid, α-synuclein, tau, huntingtin and aggregated p53 in cancer cells.

The Seprion ligands have been used extensively in commercial BSE screening and in research applications such as the screening of tonsils for vCJD or in mouse models of various Protein Aggregation Diseases.

The Seprion ligands are supplied coated onto magnetic beads or onto 96-well microplates which gives the researcher the flexibility of separation and assay format.

Seprion ligand for the study of Protein Aggregation Diseases

These kits easily and efficiently enable the detection of abnormal aggregated protein. Applications include the study and monitoring of Protein Aggregation Diseases in human and animal samples and drug screening in vitro and in vivo. To date the Seprion ligand products have been demonstrated to work with p53 in cancer, β-amyloid, tau, α-synuclein, huntingtin and prion proteins. Evaluation kits are available for other applications.

Detection of aggregates in the production of therapeutic proteins.

The Seprion-coated magnetic beads, PAD-beads extract aggregated proteins from a larger volume of sample. After capturing onto the bead, the aggregates are eluted and detected in an ELISA that is specific for the protein of interest.